34. Consolidated Companies as of December 31, 2025
Name of the subsidiary |
Country |
% voting right |
Change in % voting |
|---|---|---|---|
GLPG US Inc. (formerly AboundBio Inc.) |
United States |
100% |
|
Galapagos B.V. (merged with CellPoint B.V.) |
The Netherlands |
100% |
|
Galapagos GmbH |
Switzerland |
100% |
|
GLPG US Holding Inc. |
United States |
100% |
|
Galapagos NV |
Belgium |
Parent company |
|
Galapagos Real Estate Belgium BV |
Belgium |
0% |
(100%) |
Galapagos Real Estate Netherlands B.V. |
The Netherlands |
100% |
|
Galapagos U.K. Limited |
United Kingdom |
100% |
|
Galapagos SASU |
France |
100% |
|
Xenometrix, Inc. in liquidation |
United States |
100% |
|
Galapagos Holding PTE. LTD. |
Singapore |
100% |
|
Lakefront Biotherapeutics, Inc. |
United States |
100% |
100% |
Galapagos Cell Therapeutics NV |
Belgium |
100% |
100% |
Galapagos (Shanghai) Bioscience Co., Ltd. |
People’s Republic |
100% |
100% |
There are no significant restrictions on the group’s ability to access or use assets, or settle liabilities, of one of the group’s subsidiaries.
In December 2024, we signed a share purchase agreement regarding the shares of Galapagos Real Estate Belgium BV. The transaction was closed on March 31, 2025.
On January 7, 2025, we incorporated Galapagos (Shanghai) Bioscience Co., Ltd., in the People’s Republic of China, and on February 14, 2025 we incorporated Galapagos Cell Therapeutics NV (formerly XYZ Spinco NV) in Belgium. On August 5, 2025, we incorporated Lakefront Biotherapeutics, Inc. in the United States.